Introduction
Proteinase 3 (PR3) is an abundant serine proteinase, stored in the azurophilic granules of neutrophils, that is released onto the cell surface on activation. [1] [2] [3] Proteinase 3 (PR3) expression on neutrophils was examined in rheumatoid arthritis (RA) patients before and after antitumor necrosis factor (TNF)-α therapy. Membrane PR3 expression from patients with either an infection or RA significantly increased. Membrane PR3 expression on neutrophils from RA patients treated with infliximab (anti-TNF-α antibody) therapy was less than in those without such treatment in a resting state, but the expression later increased after stimulation in vitro. Membrane PR3 expression increased because of the stimulation of TNFα, whereas it was significantly suppressed by plasma or α 1 -proteinase inhibitor. The condition of patients with RA improved after treatment with infliximab. Membrane PR3 expression on neutrophils in RA patients was downregulated by infliximab. As a result, PR3 might play an important role in the neutrophil-mediated inflammatory reaction in patients with either RA or an infection. Keywords: proteinase 3; infliximab; rheumatoid arthritis; cytokine; neutrophil that PR3 expression might also increase in other inflammatory diseases.
So far, there are only a few reports regarding PR3 expression in patients with common inflammatory disorders such as infection or rheumatoid arthritis (RA). It is well established that proinflammatory cytokines, such as tumor necrosis factor (TNF), interleukin-β (IL-1β), and IL-6, play an important role in the induction and maintenance of rheumatoid synovitis. 10 The treatment of RA patients with TNF blockers results in a significant clinical benefit. 11 PR3 might play an important role in the neutrophil-mediated inflammatory reaction in patients not only with PR3-ANCA-positive vasculitis but also with common inflammatory diseases such as RA.
In this study, we examined PR3 expression on neutrophils in RA patients before and after anti-TNF-α therapy and then compared the findings with those in healthy donors and other infectious patients.
Materials and Methods

Healthy Volunteers and Patients
The expression of PR3 on neutrophils was examined in 28 healthy volunteers (17 men and 11 women) aged 19 to 23 years (mean age, 21.5 ± 1.1 years). The patient group consisted of 29 patients with infectious diseases (25 men and 4 women; mean age, 58.4 ± 18.1 years; age range, 20 to 84 years). RA patients before infliximab (Remicade; Tanabe, Osaka, Japan) therapy (8 women; mean age, 51.9 ± 5.9 years; age range, 44 to 64 years) and after treatment with infliximab (1 man and 11 women; mean age, 54.1 ± 7.7 years; age range, 43 to 67 years) were observed (Tables 1 and 2). Infliximab was administered intravenously at a dosage of 3 mg/kg according to a schedule with initial infusions at 0, 2, and 6 weeks, combined with methotrexate (Rheumatrex; Wyeth Japan, Tokyo, Japan), followed by further administrations once every 8 weeks. All patients and healthy donors gave their informed consent before participating in the study, and the study was approved by Mie University's Human Ethics Review Committee.
Materials
Dextran was purchased from Wako (Osaka, Japan). Hank's balanced salt solution (HBSS) was from Gibco BRL (Grand Island, NY). Recombinant TNF-α was from Peprotech EC (London, UK). IL-1β, IL-6, IL-8, interferon-α (IFN), and N-formyl-L-methionyl-L-phenylalanine (FMLP) were from Sigma-Aldrich (St Louis, Mo). α 1 proteinase inhibitor (α 1 PI; α 1 antitrypsin) was purchased from EMD Biosciences (Darmstadt, Germany). Activated protein C (APC) was donated by Kaketsuken (Kumamoto, Japan). Antithrombin (AT; Neuart) was donated by Mitsubishi Pharma (Osaka, Japan).
Monoclonal antibody 1549, which recognizes human PR3, was obtained from hybridoma supernatants using mice immunized with PR3 purified from human neutrophils (Athens Research, Athens, Ga). Supernatants were screened for binding to neutrophil-derived PR3 immobilized in wells in 96-well plates, and bound antibody was detected with horseradish peroxidase-conjugated goat antimouse IgG and substrate. Monoclonal antibody 1549 does not recognize neutrophil elastase (data not shown). For production, hybridoma cells were cultured in bags (I-MAB Monoclonal Antibody Production Kit; Diagnostic Chemicals, Oxford, Conn) in RPMI-1640, 10% bovine calf serum, 50 U/mL penicillin, 50 μg/ mL streptomycin, and 0.35 mg/mL L-glutamine. The antibodies were purified from conditioned media using Mep Hypercel resin (Life Technologies, Gaithersburg, Md) equilibrated in 50 mM Tris-HCl, pH 7.5, 0.1 M NaCl, 0.02% sodium azide and eluted with 50 mM sodium acetate, pH 4.0. Antibody was labeled for flow cytometry studies with Alexa488-6succinimidyl ester conjugate (Molecular Probes, Eugene, Ore) using standard methods and a free probe was removed with extensive dialysis.
Neutrophil Isolation
For experiments using purified neutrophils, ethylenediaminetetraacetic acid anticoagulated whole blood was mixed with a half volume of 2% dextran in 0.9% NaCl. Then red blood cells were allowed to settle for 45 to 60 minutes at room temperature. The supernatant was removed and centrifuged at 400g (5 minutes, 4°C). The pellet was resuspended in 5 mL of ice-cold 0.2% NaCl with mixing for 25 seconds, followed by 5 mL of ice-cold 1.6% NaCl. The cells were centrifuged and the pellet gently resuspended in 1 mL of HBSS with calcium containing 1% bovine serum albumin (HBSS+ buffer). Next, the sample was centrifuged at 400g (5 minutes at 4°C). The pellet containing purified neutrophils was resuspended in HBSS+ buffer.
In Vitro Stimulation Experiments and the Measurement of Membrane PR3 Expression by Flow Cytometry
The isolated neutrophils were resuspended in HBSS+ buffer at a final concentration of 2 × 10 6 /mL. The cell suspension was incubated with various stimuli in polypropylene tubes and then washed with 1 mL ice-cold HBSS+ buffer. Both during and after incubation, various inhibitors such as plasma were added and then washed with 1 mL ice-cold HBSS+ buffer. The cells were pelleted and resuspended in HBSS+ buffer before they were incubated with a dilution of monoclonal Alexa 488-labeled antibody to PR3 in polystyrene tubes. Data acquisition by flow cytometry and subsequent analyses were done on the same day with a FACScan using the CellQuest software package (Becton Dickinson, Heidelberg, Germany). Neutrophils were gated according to their relative size (forward scatter) and relative granularity (side scatter) properties. All data were reported as the mean fluorescence intensity (MFI), thus reflecting the total amount of membrane PR3 expression.
Statistical Analysis
Differences in the continuous variables between the two groups were analyzed by means of the Mann-Whitney U test. Two-sided P < .05 was considered to be statistically significant. Figure 1 shows the membrane PR3 expression on neutrophils from a healthy donor and 3 patients with inflammatory disease. Purified neutrophils were stained for membrane PR3 either with stimulation (activated) or without stimulation (resting) by 1 ng/mL TNF-α and 1 μM FMLP in vitro. Membrane PR3 expression on neutrophils increased after stimulation in vitro; however, the expression without stimulation was very small. Membrane PR3 expression from patients with infection ( Figure 1B) or RA patients without infliximab therapy ( Figure 1C ) was much larger than in healthy donors ( Figure 1A) regardless of whether or not stimulation was performed in vitro. Membrane PR3 expression on neutrophils from RA patients with infliximab therapy was less than in those without it ( Figure 1C ) in a resting state, but it increased after stimulation in vitro ( Figure 1D ). Figure 2 shows the amount of membrane PR3 expression on neutrophils from healthy donors with various stimuli for 20 minutes at 37°C. Membrane PR3 expression (MFI) significantly increased after incubation with various proinflammatory cytokines such as TNF-α (10 ng/mL), IL-1β (10 ng/mL), IL-6 (10 ng/mL), IL-8 (10 ng/mL), and IFN-α (20 U/mL).
Results
Increasing Membrane PR3 Expression on Neutrophil Stimulated by Various Proinflammatory Cytokines In Vitro
The Suppression of Membrane PR3 Expression on Neutrophils by Plasma and Protease Inhibitor
Purified neutrophils from 3 healthy donors were stimulated by 1 ng/mL TNF-α and 1 μM FMLP with or without plasma from healthy donors or 10 μM α 1 PI. The increase in membrane PR3 expression after stimulation by TNF and FMLP was significantly suppressed by plasma or α 1 PI but not APC or AT (Figure 3 ). Figure 4 shows membrane PR3 expression on neutrophils from patients with RA or infectious diseases. Membrane PR3 expression on neutrophils in patients with infection (165.09 ± 102.78) and RA patients without infliximab therapy (101.80 ± 43.67) were significantly higher than in healthy donors (28.57 ± 18.83). Remarkably, membrane PR3 expression in RA patients with infliximab therapy (39.82 ± 24.09) was significantly lower than in those without it. In addition, the condition of the patients with RA improved after treatment with infliximab.
Neutrophil Membrane PR3 Expression From Healthy Donors, Patients With RA, or Patients With Infectious Disease
Discussion
Previous reports have shown that an elevated level of membrane PR3 expression is related to disease and relapse in patients with PR3-ANCA-associated vasculitis containing WG. [12] [13] [14] Our findings have shown that membrane PR3 expression on neutrophils is significantly higher in patients with more common diseases, such as infection or RA. These patients did not include those with PR3-ANCAassociated vasculitis. PR3 expression on neutrophils increased in relation to the C-reactive protein (CRP) concentration (data not shown). A previous study reported that PR3 expression on neutrophils closely correlated with CRP in patients with infections. 9 These findings suggest that an elevated expression of PR3 on neutrophils is a good marker, which may also play an important role in these diseases. Elevated levels of cytokines, such as TNF-α, have been reported in RA patients 15 and in septic patients with disseminated intravascular coagulation. 16 The amount of PR3 expression on neutrophils significantly increased with the addition of various cytokines such as TNF-α, IL-1β, IL-6, IL-8, or IFN-α. A previous report showed that membrane PR3 expression on neutrophils was upregulated by proinflammatory mediators such as TNF-α, IL-1β, or IL-6. 17 TNF-α is produced as a membrane-bound proform, which needs to be cleaved proteolytically to be released in its major biologically active form. PR3 is able to process TNF-α in vitro into its active form. 18 The expression of PR3 on neutrophils was markedly suppressed with the addition of plasma. The expression of PR3 was suppressed by α 1 PI but not AT or APC. These findings are consistent with those of previous reports, 19 indicating that the main inhibitor of membrane PR3 on neutrophils is α 1 PI. α 1 PI, which is mainly synthesized in the liver and occurs in high concentrations in plasma, inhibits PR3 activity very quickly. 20 Anti-TNF-α treatment has been reported to be successful in patients with RA. 9,10 Our present findings show that membrane PR3 expression on neutrophils is downregulated in RA patients by treatment with infliximab, suggesting that anti-TNF antibody suppresses PR3 expression in RA patients. Therefore, after activation with TNF-a and FMLP, no significant difference was observed between RA patients with and without treatment with Remicade. These findings show that the addition of TNF neutralizes anti-TNF antibodies in patients. In these patients, both the condition of the patients and CRP concentration improved. Thus, anticytokine therapy or substitution therapy using protease inhibitors might be more effective for the treatment of infectious diseases in which PR3 is related to the clinical condition. Indeed, infliximab was reported to be effective in the treatment of a case of refractory WG by improving the kidney function and also inducing clinical remission. 21 Membrane PR3 expression on neutrophils in an RA patient was downregulated by anti-TNF antibody therapy. Therefore, PR3 might play an important role in the neutrophil-mediated inflammatory reaction not only in PR3-ANCA-associated vasculitis but also in more common diseases such as RA and infection.
